journal article·2025-11Open access

Histone Lactylation‐Driven Upregulation of VRK1 Expression Promotes Stemness and Proliferation of Glioma Stem Cells

Jinna Li, Chenyue Tang, Xuefeng Zhang, Rui Xing, Qing Guo

Advanced Science· Volume 12· Issue 44
This record is marked as retracted by the source. Review the publisher’s notice before using its findings.

Abstract

Abstract Glioblastoma (GBM) is the most malignant primary brain tumor in adults, with glioma stem cells (GSCs) as a subpopulation contributing to treatment resistance and recurrence. This study investigates the role of lactate and its regulatory gene, vaccinia‐related kinase 1 ( VRK1 ), in the regulation of GSC stemness. Utilizing multiple glioma‐related databases and patient‐derived GSCs, it is discovered that lactate enhances the stemness and proliferation of GSCs via VRK1. Mechanistically, lactate promotes histone lactylation (H3K18la) at the VRK1 promoter in GSCs, thereby upregulating VRK1 expression. VRK1 enhances Y‐box binding protein 1 (YBX1) protein stability by inhibiting its ubiquitination and degradation, and phosphorylates YBX1 to promote its nuclear translocation, thereby regulating GSC stemness and proliferation via the YBX1/SOX2 pathway. Additionally, the VRK1‐targeted nanoliposome A/TMZ‐siVRK1 effectively suppresses the stemness and proliferation of GSCs, demonstrating its therapeutic potential. In conclusion, lactate regulates the stemness and proliferation of GSCs via the H3K18la/VRK1/YBX1/SOX2 pathway. This study elucidates the role of histone lactylation in stem cell regulation and suggests that VRK1 is a potential therapeutic target for GBM.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nuclear Structure and Function · RNA Research and Splicing · Genomics and Chromatin Dynamics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Oncology Shengjing Hospital of China Medical University Shenyang Liaoning 110004 China

Department of Neurosurgery The First Hospital of China Medical University Shenyang Liaoning 110001 China

Institute of Nervous System Diseases Xuzhou Medical University Xuzhou Jiangsu 221002 China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Liaoning Province

References (65)

Show source-provided references
1. 10.1093/neuonc/noae14510.1093/neuonc/noae145 ↗
2. 10.1038/s41423-024-01226-x10.1038/s41423-024-01226-x ↗
3. 10.1186/s12943-022-01513-z10.1186/s12943-022-01513-z ↗
4. 10.1002/ijc.2880410.1002/ijc.28804 ↗
5. 10.1093/neuonc/noae01110.1093/neuonc/noae011 ↗
6. 10.1093/neuonc/noaa25910.1093/neuonc/noaa259 ↗
7. 10.1101/gad.261982.11510.1101/gad.261982.115 ↗
8. 10.7150/thno.4169210.7150/thno.41692 ↗
9. 10.3389/fimmu.2018.0292410.3389/fimmu.2018.02924 ↗
10. 10.1016/j.cell.2014.02.03010.1016/j.cell.2014.02.030 ↗
11. 10.1016/j.apsb.2023.12.00310.1016/j.apsb.2023.12.003 ↗
12. 10.1016/j.semcancer.2022.10.00910.1016/j.semcancer.2022.10.009 ↗
13. 10.1002/nbm.319810.1002/nbm.3198 ↗
14. 10.1007/s11306-016-1055-010.1007/s11306-016-1055-0 ↗
15. 10.1111/1759-7714.1371110.1111/1759-7714.13711 ↗
16. 10.1016/j.yexcr.2016.01.00510.1016/j.yexcr.2016.01.005 ↗
17. 10.1177/263485352199409410.1177/2634853521994094 ↗
18. 10.1093/neuonc/now25810.1093/neuonc/now258 ↗
19. 10.3389/fimmu.2023.89485310.3389/fimmu.2023.894853 ↗
20. 10.1172/JCI17685110.1172/JCI176851 ↗
21. 10.1038/s41586-019-1678-110.1038/s41586-019-1678-1 ↗
22. 10.3389/fimmu.2023.121122110.3389/fimmu.2023.1211221 ↗
23. 10.1016/j.molcel.2022.02.03310.1016/j.molcel.2022.02.033 ↗
24. 10.1186/s13059-021-02308-z10.1186/s13059-021-02308-z ↗
25. 10.1016/j.canlet.2020.12.03210.1016/j.canlet.2020.12.032 ↗
26. 10.1038/sj.onc.120370910.1038/sj.onc.1203709 ↗
27. 10.1074/jbc.M40100920010.1074/jbc.M401009200 ↗
28. 10.1038/sj.onc.120801510.1038/sj.onc.1208015 ↗
29. 10.1007/s00018-018-2811-210.1007/s00018-018-2811-2 ↗
30. 10.1016/j.molcel.2016.09.01210.1016/j.molcel.2016.09.012 ↗
31. 10.3892/ol.2020.1165410.3892/ol.2020.11654 ↗
32. 10.3389/fphar.2022.87423510.3389/fphar.2022.874235 ↗
33. 10.4149/neo_2021_210304N27810.4149/neo_2021_210304N278 ↗
34. 10.1016/j.prp.2017.10.01410.1016/j.prp.2017.10.014 ↗
35. 10.3389/fcell.2021.68303810.3389/fcell.2021.683038 ↗
36. 10.1016/j.tem.2022.07.00410.1016/j.tem.2022.07.004 ↗
37. 10.1016/j.isci.2022.10532910.1016/j.isci.2022.105329 ↗
38. 10.1038/s41388-022-02295-w10.1038/s41388-022-02295-w ↗
39. 10.1038/s41392-022-01151-310.1038/s41392-022-01151-3 ↗
40. 10.1016/j.molcel.2022.06.03010.1016/j.molcel.2022.06.030 ↗
41. 10.1016/j.ccell.2017.06.00310.1016/j.ccell.2017.06.003 ↗
42. 10.1038/s41588-021-00926-810.1038/s41588-021-00926-8 ↗
43. 10.1126/sciadv.abi669610.1126/sciadv.abi6696 ↗
44. 10.1016/j.cell.2022.11.02610.1016/j.cell.2022.11.026 ↗
45. 10.1158/0008-5472.CAN-21-444310.1158/0008-5472.CAN-21-4443 ↗
46. 10.1038/s41420-023-01302-710.1038/s41420-023-01302-7 ↗
47. 10.1002/advs.20241439810.1002/advs.202414398 ↗
48. Liang B.‐G. · Hepatology · 2025
49. Hong X. · Clin. Cancer Res. · 2022 · 28 · 521
50. 10.1016/j.biomaterials.2021.12116310.1016/j.biomaterials.2021.121163 ↗
51. 10.1111/cpr.1347810.1111/cpr.13478 ↗
52. 10.3390/ijms2607336810.3390/ijms26073368 ↗
53. 10.3389/fonc.2022.87179810.3389/fonc.2022.871798 ↗
54. 10.1073/pnas.200977811710.1073/pnas.2009778117 ↗
55. 10.1186/1471-2407-14-32810.1186/1471-2407-14-328 ↗
56. 10.1158/0008-5472.CAN-10-280510.1158/0008-5472.CAN-10-2805 ↗
57. 10.1186/s13287-019-1360-410.1186/s13287-019-1360-4 ↗
58. 10.1038/s41586-020-2968-310.1038/s41586-020-2968-3 ↗
59. 10.1158/1535-7163.MCT-19-069010.1158/1535-7163.MCT-19-0690 ↗
60. 10.1038/s41419-023-05605-610.1038/s41419-023-05605-6 ↗
61. 10.1186/s13578-022-00912-510.1186/s13578-022-00912-5 ↗
62. 10.1126/sciadv.abd688910.1126/sciadv.abd6889 ↗
63. 10.1371/journal.pone.002323510.1371/journal.pone.0023235 ↗
64. 10.1093/neuonc/now24710.1093/neuonc/now247 ↗
65. 10.1038/s41419-024-06469-010.1038/s41419-024-06469-0 ↗